July 16, 2021
Enzymatica Interim Report January - June 2021
April 29, 2021
Enzymatica Interim Report January - March 2021
March 31, 2021
Enzymatica Annual Report 2020
February 18, 2021
Enzymatica Year-End Report 2020
November 2, 2021
Interim report January - September 2021
February 17, 2022
Year end report 2021


Enzymatica wants to be a good stakeholder in the community and take responsibility for sustainable social development.

As a medical device company, Enzymatica focuses on human health and well-being, and wants to use resources, regardless of whether they are raw materials, energy or human, as wisely and sustainably as possible.

Regarding basic research, production and sales of products, the Company cooperates to a large extent with partners, many of whom actively work with sustainability issues.

ColdZyme® against common cold

ColdZyme reduces the risk of catching a cold and shortens the duration of illness at an early stage of infection.


Extensive market and strong presence on the home market

Enzymatica operates on a large market, colds, with strong underlying growth. The market for over-the-counter cold products amounted to USD 21.5 billion in 2017. Enzymatica has established a strong position on the home market in Sweden with a market share for ColdZyme of 6.5%, based on rolling 12-month data at year-end 2019/2020.

We are also building a strong distributor network. In 2019 the company signed agreement with partners for a new mouth spray for the German market, and in addition agreements of enzyme formulations for the German and Chinese markets. In the beginning of 2020 Enzymatica entered into an agreement regarding ColdZyme for the Chinese market.

Contact us

Enzymatica AB
Ideon Science Park
SE-223 70 Lund, Sweden
Telefon: +46 46-286 31 00
E-mail: info@enzymatica.se

Enzymatica cares about your privacy and processes your personal data in accordance with the EU’s General Data Protection Regulation. For more information about how we handle your personal information, and what rights you have, please refer to our personal data processing document here.